Biovail receives approval for Aplenzin for depression

News
Article

Aplenzin is a new drug from Biovail Corp. that has been approved to treat depression in adults

Aplenzin (bupropion hydrobromide), formerly known as BVF-033, is an antidepressant from Biovail Corp. that has just received approval from the Food & Drug Administration. The

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Related Content
FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

April 23rd 2024
Article

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

April 19th 2024
Article

Check out important updates from the FDA for the week of April 15.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

April 16th 2024
Article

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Rx Roundup: Quiz of the Week — April 12, 2024

Rx Roundup: Quiz of the Week — April 12, 2024

April 12th 2024
Article

Test your pharmacy news knowledge with our weekly quiz.

© 2024 MJH Life Sciences

All rights reserved.